- Home
- LDI vs IMMP Comparison
LDI vs IMMP Comparison
Compare LDI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- IMMP
- Stock Information
- Founded
- LDI 2010
- IMMP 1987
- Country
- LDI United States
- IMMP Australia
- Employees
- LDI N/A
- IMMP N/A
- Industry
- LDI Finance: Consumer Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- IMMP Health Care
- Exchange
- LDI Nasdaq
- IMMP Nasdaq
- Market Cap
- LDI 894.0M
- IMMP 251.8M
- IPO Year
- LDI 2021
- IMMP N/A
- Fundamental
- Price
- LDI $4.44
- IMMP $1.69
- Analyst Decision
- LDI Sell
- IMMP Buy
- Analyst Count
- LDI 3
- IMMP 1
- Target Price
- LDI $2.30
- IMMP $7.00
- AVG Volume (30 Days)
- LDI 12.9M
- IMMP 87.2K
- Earning Date
- LDI 11-04-2025
- IMMP 10-21-2025
- Dividend Yield
- LDI N/A
- IMMP N/A
- EPS Growth
- LDI N/A
- IMMP N/A
- EPS
- LDI N/A
- IMMP N/A
- Revenue
- LDI $1,124,074,000.00
- IMMP $3,306,742.00
- Revenue This Year
- LDI $21.95
- IMMP N/A
- Revenue Next Year
- LDI $15.72
- IMMP $725.37
- P/E Ratio
- LDI N/A
- IMMP N/A
- Revenue Growth
- LDI 27.06
- IMMP 31.28
- 52 Week Low
- LDI $1.01
- IMMP $1.32
- 52 Week High
- LDI $4.87
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- LDI 78.13
- IMMP 50.87
- Support Level
- LDI $3.01
- IMMP $1.60
- Resistance Level
- LDI $4.87
- IMMP $1.76
- Average True Range (ATR)
- LDI 0.41
- IMMP 0.06
- MACD
- LDI 0.22
- IMMP 0.01
- Stochastic Oscillator
- LDI 85.27
- IMMP 58.82
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.